OncolinesProfiler™ Compound Library is approaching the 200 mark.

Clustering analysis via OncolinesProfiler™ compares your compound’s IC50 fingerprint against the cellular activity of other anti-cancer therapeutics. The OncolinesProfiler™ compound library started out as a collection of 122 standards of care, clinical stage candidates, classic cytotoxic agents and novel target & experimental therapeutics in 2016 (Uitdehaag et al., 2016) and has been a valuable tool for researchers to start differentiating their compounds.

Today, the compound library contains close to 200 anti-cancer agents such as small molecules, antibodies and ADCs.

February 4 2021:  OncolinesProfiler™ Compound Library is approaching the 200 mark. The figure to the right shows the network tree (clustering wheel) of all compounds of the OncolinesProfiler™ Compound Library. Compounds are gruped into clusters representing mechanism of action classes.

Showcase example of additions to OncolinesProfiler™ – ATR kinase inhibitors

Ceralasertib & berzosertib, two of the new additions to the OncolinesProfiler™ compound library, form a new cluster of ATR kinase inhibitors in the clustering wheel

OncolineProfiler™ Hierarchical clustering wheel. Ceralasertib is depicted in red
Network tree of ceralasertib & berzosertib  (in red) and the full compound library
Correlation matrix of ceralasertib and all reference compounds.

About Oncolines
Oncolines B.V. is a precision medicine services company in oncology and cancer immunotherapy. We help to bring improved and novel therapies to the right patient population faster. We offer a set of complimentary services to enable our clients to characterize their compounds, and to determine activities, selectivities and mechanism of action. We present results in a unique and interactive reporting format that facilitates easier and faster interpretation of results.